Lundbeck seeks approval for PTSD treatment

Danish pharmaceutical company Lundbeck, in partnership with Otsuka, has submitted a request to the U.S. authorities to approve Rexulti for treating post-traumatic stress disorder (PTSD). The medication is to be used in tandem with Sertraline, predicated on previously published trial results. Already approved for conditions such as schizophrenia and depression, Rexulti was Lundbeck’s top-selling product last year, bringing in over DKK 4.5 billion. With approximately 8 million PTSD patients in the U.S., Cita analyst Vineet R. Agrawal acknowledges a high demand for better treatments but sees limited potential due to the drug’s short patent life, expiring in 2029. Nearly a quarter of Lundbeck’s total revenue, which is around DKK 19.9 billion, comes from Rexulti, while almost half of their total earnings, DKK 9.8 billion, are generated in the U.S.